secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-05-29T20:45:58+00:00
Accession:  0001636282-26-000056
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns
--------------------------------------------------------------------------------

- Stockholders approved amended and restated 2016 ESPP (66.9M for, 45.5K against) at May 27 annual meeting.
- Director Peter Harwin resigned effective May 27, 2026; Board reduced from 8 to 7 directors.
- Elected Class I directors Mark McKenna, Cameron Turtle, and Laurie Stelzer to 2029 term.
- Non-binding advisory vote on executive compensation passed with 62.1M for, 4.8M against.
- Ratification of KPMG as independent auditor for FY2026 passed with 68.4M for, 670 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/syre-20260527.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer